An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
Monoclonal antibodies targeted to the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 monoclonal antibodies in the clinic, the experimental relationshi...
| Main Authors: | , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Taylor & Francis
2022
|
| Online Access: | https://hdl.handle.net/1721.1/144276 |